FHAM
BMRN icon

Folger Hill Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Folger Hill Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-25,000
Closed -$2.62M – 175
2015
Q4 		$2.62M Buy
+25,000
New +$2.61M 0.16% 133

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Folger Hill Asset Management's BMRN Position: Q1 2016 in Review

Folger Hill Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 25,000 shares — an estimated $2.62M sold.

Folger Hill Asset Management first reported a position in BMRN in Q4 2015 and held it in 1 quarter. The position peaked at $2.62M in Q4 2015. 390 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

  • Folger Hill Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Folger Hill Asset Management sold 25,000 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $2.62M.
  • Folger Hill Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Folger Hill Asset Management's BioMarin Pharmaceuticals position peaked at $2.62M in Q4 2015.
  • 390 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Folger Hill Asset Management's 13F filing for Q1 2016, filed 16 May 2016.